43 results
8-K
EX-99.1
ITCI
Intra-Cellular Therapies Inc
18 Jun 24
Other Events
7:37am
to falls and, consequently, fractures and other injuries. Patients should be assessed for risk when using CAPLYTA.
Seizures. CAPLYTA should be used
8-K
EX-99.1
ITCI
Intra-Cellular Therapies Inc
7 May 24
Intra-cellular Therapies Reports First Quarter 2024 Financial Results
7:40am
and, consequently, fractures and other injuries. Patients should be assessed for risk when using CAPLYTA.
Seizures. CAPLYTA should be used cautiously
8-K
EX-99.1
ITCI
Intra-Cellular Therapies Inc
16 Apr 24
Lumateperone 42 mg achieved statistically significant and clinically meaningful results in both the primary and the key secondary endpoints
7:10am
and, consequently, fractures and other injuries. Patients should be assessed for risk when using CAPLYTA.
Seizures. CAPLYTA should be used cautiously in patients
8-K
EX-99.1
ITCI
Intra-Cellular Therapies Inc
22 Feb 24
Intra-cellular Therapies Reports Fourth Quarter and Full-year 2023 Financial Results and Provides Corporate Update
7:39am
or dizziness and can slow thinking and motor skills, which may lead to falls and, consequently, fractures and other injuries. Patients should
8-K
EX-99.1
uf0duse7x5h5iqso
2 Nov 23
Intra-cellular Therapies Reports Third Quarter 2023 Financial Results and Raises 2023 Caplyta Sales Guidance
8:01am
8-K
EX-99.1
fe7 s5t3ofe7
3 Aug 23
Intra-cellular Therapies Reports Second Quarter 2023 Financial Results and Raises 2023 Caplyta Sales Guidance
7:39am
8-K
EX-99.1
uq8mxy8dpz iz
4 May 23
Intra-cellular Therapies Reports First Quarter 2023 Financial Results and Provides Corporate Update
7:37am
8-K
EX-99.1
431su58n 3y4
3 Nov 22
Intra-cellular Therapies Reports Third Quarter 2022 Financial Results and Provides Corporate Update
7:35am
8-K
EX-99.1
j066p01ji2d2
9 Aug 22
Intra-cellular Therapies Reports Second Quarter 2022 Financial Results and Provides Corporate Update
7:38am
8-K
EX-99.1
28ml181jy6vneve76jaf
10 May 22
Intra-cellular Therapies Reports First Quarter 2022 Financial Results and Provides Corporate Update
7:37am
8-K
EX-99.1
6auhazoz
25 Apr 22
Intra-Cellular Therapies Announces FDA Approval of New Dosage Strengths for CAPLYTA® (lumateperone) for Specific Patient Populations
7:12am
8-K
EX-99.1
eaw 3gkgy9
1 Mar 22
Intra-cellular Therapies Reports Fourth Quarter and Full-year 2021 Financial Results and Provides Corporate Update
7:49am
424B5
6rolaw
5 Jan 22
Prospectus supplement for primary offering
4:51pm
424B5
vib4hkrxrf rg
3 Jan 22
Prospectus supplement for primary offering
5:30pm
8-K
EX-99.1
6a3xwke6zj4eaq2
20 Dec 21
Intra-Cellular Therapies Announces U.S. FDA Approval of CAPLYTA® (lumateperone) for the Treatment of Bipolar Depression in Adults
7:04am
8-K
EX-99.1
1g7tdkplemaljlsii
9 Nov 21
Intra-cellular Therapies Reports Third Quarter 2021 Financial Results and Provides Corporate Update
7:49am
8-K
EX-99.1
49hmakovv r1qlq4q
9 Aug 21
Intra-cellular Therapies Reports Second Quarter 2021 Financial Results and Provides Corporate Update
7:37am
8-K
EX-99.1
9xvf nbhe4no
10 May 21
Intra-cellular Therapies Reports First Quarter 2021 Financial Results and Provides Corporate Update
7:37am